ReviewAntibody therapeutics2021
Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
Haiyong PengPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this papertrialcites it